Administration of Ferric Citrate Hydrate Decreases Circulating FGF23 Levels Independently of Serum Phosphate Levels in Hemodialysis Patients with Iron Deficiency

Publisher： Karger

E-ISSN： 2235-3186|131|3|161-166

ISSN： 1660-8151

Source： Nephron, Vol.131, Iss.3, 2015-0, pp. : 161-166

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis

By  

American Journal of Nephrology, Vol. 44, Iss. 5, 2016-10 ,pp. : 404-410

Karger

Access to resources Recommend Favorite

Treatment with Sevelamer Decreases Bicarbonate Levels in Hemodialysis Patients

By  

Nephron, Vol. 92, Iss. 2, 2002-09 ,pp. : 499-500

Karger

Access to resources Recommend Favorite

Higher Serum Bisphenol A Levels in Diabetic Hemodialysis Patients

By  

Blood Purification, Vol. 42, Iss. 1, 2016-05 ,pp. : 77-82

Karger

Access to resources Recommend Favorite

Oral Low-Dose Ferric Citrate Is a Useful Iron Source for Hyperphosphatemic Hemodialysis Patients: A Case Series

By  

Blood Purification, Vol. 43, Iss. 1-3, 2016-12 ,pp. : 97-100

Karger

Access to resources Recommend Favorite

Correlation of Serum Magnesium and Serum Lipid Levels in Hemodialysis Patients

By  

Nephron, Vol. 78, Iss. 1, 1997-12 ,pp. : 118-119

Karger

Access to resources Recommend Favorite